Please assess the completion status of the following clinical trial:

Trial Title: A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be willing and able to give written informed consent, adhere to trial procedures and able to read and understand English.~* Male and female participants 18 to 65 years of age.~* Participants must possess a smartphone and is familiar with its use and is willing to download and interact with the Abilify MyCite® app. Participants with a smartphone, that is not compatible with the Abilify MyCite® app will be offered a loaner phone for the trial period.~* Clinical diagnosis of schizophrenia and able to ingest oral medication.~* Positive and Negative Syndrome Scale (PANSS) total score between 60-90.~* Participants currently prescribed oral atypical antipsychotic medication including aripiprazole or appropriate for aripiprazole treatment for 6 months or longer.~* Participants are required to have had an inpatient hospitalization for schizophrenia within the last 48 months prior to entering the trial.~* Skin on the anterior chest just above the lower edge of the rib cage that is free of any dermatological problems.~Exclusion Criteria:~* Females who are breast-feeding and/or who are pregnant.~* Sexually active males or women of childbearing potential (WOCBP) who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose of Abilify MyCite®.~* Any participants who participated in another clinical trial within 30 days of enrollment.~* Participants who are currently being treated with an LAI antipsychotic or have been treated with an LAI in the retrospective 6-month phase.~* Participants with a current DSM-5 diagnosis other than schizophrenia.~* Participants with a known allergy to adhesive tape or any pertinent components of the patch or aripiprazole tablet embedded with an IEM sensor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Abilify MyCite® (Type: EXPERIMENTAL): Participants received Abilify MyCite® a combination product of aripiprazole tablet embedded with sensor and wearable patch for 3 months (Months 1 to 3) and continued for an additional 3 months (Months 4 to 6) as per investigators assessment or switch to a standard-of-care treatment of oral atypical antipsychotics or a long acting injectable.

Based on this trial design, predict the completion outcome and termination type (if applicable).